BiomX, Inc.
🇺🇸United States
A Study of Topical BX005-A in Subjects With Moderate to Severe Atopic Dermatitis
Phase 1
- Conditions
- Atopic Dermatitis
- Interventions
- Other: PlaceboBiological: BX005-A
- First Posted Date
- 2022-02-15
- Last Posted Date
- 2022-02-15
- Lead Sponsor
- BiomX, Inc.
- Target Recruit Count
- 48
- Registration Number
- NCT05240300
Nebulized Bacteriophage Therapy in Cystic Fibrosis Patients With Chronic Pseudomonas Aeruginosa Pulmonary Infection
Phase 1
Active, not recruiting
- Conditions
- Chronic Pseudomonas Aeruginosa InfectionCystic Fibrosis
- Interventions
- Drug: Placebo
- First Posted Date
- 2021-08-18
- Last Posted Date
- 2023-10-18
- Lead Sponsor
- BiomX, Inc.
- Target Recruit Count
- 32
- Registration Number
- NCT05010577
- Locations
- 🇺🇸
Boston Children's Hospital, Boston, Massachusetts, United States
🇺🇸University Hospitals Rainbow Babies and Children's Hospital, Cleveland, Ohio, United States
🇺🇸Nationwide Children's Hospital, Columbus, Ohio, United States
A Study to Evaluate the Safety, Tolerability, and Fecal Pharmacokinetics of BX002-A in Healthy Adults
Phase 1
Completed
- Conditions
- Healthy Volunteers
- Interventions
- Biological: BX002-AOther: Placebo
- First Posted Date
- 2021-02-04
- Last Posted Date
- 2022-01-25
- Lead Sponsor
- BiomX, Inc.
- Target Recruit Count
- 18
- Registration Number
- NCT04737876
- Locations
- 🇺🇸
Medical Facility, Cincinnati, Ohio, United States
© Copyright 2025. All Rights Reserved by MedPath